CRISPR-mediated rapid arming of poxvirus vectors enables facile generation of the novel immunotherapeutic STINGPOX.
Whelan JT, Singaravelu R, Wang F, Pelin A, Tamming LA, Pugliese G, Martin NT, Crupi MJF, Petryk J, Austin B, He X, Marius R, Duong J, Jones C, Fekete EEF, Alluqmani N, Chen A, Boulton S, Huh MS, Tang MY, Taha Z, Scut E, Diallo JS, Azad T, Lichty BD, Ilkow CS, Bell JC.
Whelan JT, et al. Among authors: wang f.
Front Immunol. 2023 Jan 13;13:1050250. doi: 10.3389/fimmu.2022.1050250. eCollection 2022.
Front Immunol. 2023.
PMID: 36713447
Free PMC article.